Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line art in South Africa

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  El Khatib, Ziad ^a,b   Katzenstein, David ^c   Marrone, Gaetano ^a   Laher, Fatima ^d   Mohapi, Lerato ^d   Petzold, Max ^a,e   Morris, Lynn ^b   Ekström, Anna Mia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; FEMALE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ADHERENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SOUTH AFRICA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT REFUSAL; VIROLOGY; WORLD HEALTH ORGANIZATION; ADOLESCENT; DEMOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; MIDDLE AGED; SELF REPORT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEMOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SELF REPORT; SOUTH AFRICA; TREATMENT FAILURE; YOUNG ADULT;

EID: 79952424135     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017518     Document Type: Article

References (57)

1. World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS, UNICEF (2008) Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report pp. 1-77.
2. Harries AD, Zachariah R, van Oosterhout JJ, Reid SD, Hosseinipour MC, et al. (2010) Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis 10: 60-65.
3. Simon V, Ho DD, Karim QA, (2006) HIV/AIDS epidemiology, pathogensis, prevention, and treatment. Lancet 368.
4. Kuritzkes DR, (2004) Preventing and managing antiretroviral resistance. AIDS Patient Care STDs 18: 259-273.
5. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, et al. (2007) HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 44: 128-134.
6. Rewari B, Bachani D, Rajasekaran S, Deshpande A, Chan P, et al. (2010) Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. J Acquir Immune Defic Syndr Oct 1 [Epub ahead of print].
7. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, et al. (2009) Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 49: 454-462.
8. Hosseinipour MC, van Oosterhout JG, Weigel R, Phiri S, Kamwendo D, et al. (2009) The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23: 1127-1134.
9. World Health Organization (WHO) (2006) HIV drug resistance early warning indicators (HIVDR-EWI).
10. Hedt BL, Wadonda-Kabondo N, Makombe S, Harries AD, Schouten EJ, et al. (2008) Early warning indicators for HIV drug resistance in Malawi. Antivir Ther 13 (Suppl 2): 69-75.
11. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer S, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
12. Cambiano V, Lampe F, Rodger A, Smith C, Geretti A, et al. (2010) Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med 11: 216-224.
13. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316.
14. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM, (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10: 155-166.
15. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS 24: 1679-1687.
16. Hatano H, Delwart EL, Norris PJ, Lee TH, Neilands TB, et al. (2010) Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS.
17. Hammer SM, Eron JJ J, Reiss P, Schooley RT, Thompson MA, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555-570.
18. Rothman KJ, Boice J, (1982) Epidemiologic analysis with a programmable calculator, 2nd ed. Newton, MA, Epidemiology resources.
19. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, et al. (2010) Viremia and drug resistance among HIV-1 patients on antiretroviral treatment - a cross-sectional study in Soweto, South Africa. AIDS 24.
20. Martinson NA, Morris L, Johnson J, Gray GE, Pillay V, et al. (2009) Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. AIDS 23: 809-816.
21. El-Khatib Z, DeLong AK, Katzenstein D, Ekstrom AM, Ledwaba J, et al. (2010) Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. In review.
22. El-Khatib Z, Ekstrom AM, Laher F, Karstaedt AS, Petzold M, et al. (2009) Medical review-South African adherence and virologic evaluation (MR. SAVE) tool. 1.0 ed. Stockholm: Creative Commons (CC); ziad.khatib@gmail.com.
23. El-Khatib Z, (2004) Questionnaire design and data entry in EpiData (http://onkpat.ki.se/1?node=47234). Stockholm, Sweden: Division of Clinical Cancer Epidemiology- Karolinska Institutet.
24. EpiData foundation (2008) EpiData for data entry and documentation (www.epidata.dk). Denmark.
25. World Health Organization (WHO) (2004) Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach: 2003 revision. Geneva, Switzerland WHO.
26. Paredes R, Clote B, Ruiz L, (2004) Comparison of the efficacy of HAART: single, dual or triple-class antiretroviral therapy. In: De Clercq E, Vandamme AM, editors. Combination therapy of AIDS Birkhauser Verlag/Switzerland pp. 53-71.
27. Datay MI, Boulle A, Mant D, Yudkin P, (2010) Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 54: 489-495.
28. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, et al. (2009) Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to Nonnucleoside Reverse-Transcriptase Inhibitor-based therapy. Clin Infect Dis 48: 462-472.
29. Ford N, Darder M, Spelman T, Maclean E, Mills E, et al. (2010) Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One 5: e10460 doi:10410.11371/journal.pone.0010460.
30. Boulle A, Van Cutsem G, Hilderbrand K, Cragg C, Abrahams M, et al. (2010) Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 24: 563-572.
31. StataCorp LP, (2008) Stata/SE 10.1, College Station, TX 77845 USA.
32. Prism G, (2005) version 4.0c. La Jolla, CA 92037 USA.
33. World Health Organization (WHO) (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Geneve.
34. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, et al. (2009) Long-term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc 12: 38.
35. Keiser O, Orrell C, Egger M, Wood R, Brinkhof MW, et al. (2008) Public-health and individual approaches to antiretroviral therapy: Township South Africa and Switzerland compared. PLoS Med 5: e148.
36. Lampe FC, Harding R, Smith CJ, Phillips AN, Johnson M, et al. (2010) Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr.
37. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, et al. (2006) Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 166: 521-528.
38. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, et al. (2001) Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 15: 2385-2395.
39. Datay M, Boulle A, Mant D, Yudkin P, (2010) Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes 54: 489-495.
40. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, et al. (2000) Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14: F111-115.
41. Eshleman S, Hoover D, Chen S, Hudelson S, Guay L, et al. (2005) Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19: 2167-2169.
42. Madge S, Smith C, Lampe F, Sabin C, Youle M, et al. (2008) An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy. HIV Med 9: 208-213.
43. Taiwo BO, Murphy RL, (2008) Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa. Clinical Cytometry 74B: S11-S18.
44. Egger M, (2007) Outcomes of antiretroviral treatment in resource limited and industrialized countries. CROI Los Angeles, USA.
45. Bisson G, Gross R, Bellamy S, Chittams J, Hislop M, et al. (2008) Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 5: e109.
46. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD, (2008) Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 22: 1971-1977.
47. Badri M, Lawn S, Wood R, (2008) Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 8.
48. Kagee A, Remien RH, Berkman A, Hoffman S, Campos L, et al. (2010) Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Glob Public Health pp. 1-15.
49. Nattrass N, (2006) AIDS, science and governance: the battle over antiretroviral therapy in post-apartheid South Africa. Southern African Journal of HIV Medicine Accessedhttp://www.aidstruth.org/documents/nattrass.pdf.
50. Richard T, Lester PR, Mills Edward J, Kariri Antony, Karanja Sarah, Chung Michael H, et al. (2010) Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet DOI:10.1016/S0140-6736(10)61997-6.
51. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 136: 21-30.
52. Low-Beer S, Yip B, O'Shaughnessy M, Hogg R, Montaner J, (2000) Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 23: 360-361.
53. Nachega JB, Mills EJ, Schechter M, (2010) Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 5: 70-77.
54. Shuter J, Sarlo J, Kanmaz T, Rode R, Zingman B, (2007) HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 45: 4-8.
55. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-574.
56. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, et al. (2008) Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: A prospective cohort study. AIDS Res Hum Retrovirus 24: 1263-1268.
57. Unge C, Sodergard B, Marrone G, Thorson A, Lukhwaro A, et al. (2010) Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study. PLoS One 5: e13613 doi:13610.11371/journal.pone.0013613.